Cybin provides corporate update and highlights key upcoming milestones across its development pipeline

Toronto--(business wire)--cybin inc. (nyse american:cybn) (neo:cybn) (“cybin” or the “company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options, today provided an update on its clinical-stage programs and key upcoming milestones across its development pipeline. “the clinical progress we have made over the past few months is truly remarkable, exemplified by our recently.
CYBN Ratings Summary
CYBN Quant Ranking